Ann: New Analyst Report

Updated report from NDF research out today

http://www.ndfresearch.com/uploads/...2_15_suda_update_report_from_ndf_research.pdf



If SUDA is so good, how come the market capitalisation of the company is only A$17.1m/US$13.4m?
We think the current low market capitalisation of SUDA mostly reflects the fact that it has only struck its landmark partnering deals in 2016 and 2017, after around three years of work on its drug reformulation technology. We think that with subsequent deals the stock can significantly re-rate, particularly as the company does more work on marketing the story to the investment community